Dr. John Fruehauf, field medical director at Evolent, and specialist in melanoma, spoke to DocWire News about some of the challenges associated with treating melanoma in stage III disease, and about the NADINA trial, which demonstrated the robust efficacy of neoadjuvant nivolumab in combination with ipilimumab in the treatment of stage III melanoma. The trial findings, which Dr. Fruehauf details, represent a new standard of care in melanoma.
Health Professionals
Radiomic Biomarkers Predict Response in Lung and Liver Uveal Melanoma Metastases
Radiomic biomarkers can be leveraged to predict treatment response through assessments of tumor growth in patients with metastatic uveal melanoma treated with roginolisib (IOA-244), according to findings from a study that were presented at the 2024 SITC Annual Meeting.
IMA203 Shows Frequent, Enduring Responses and Tolerability in Melanoma
Phase 1 data highlight a manageable safety profile with IMA203 among patients with melanoma and other PRAME-positive solid tumors.
Risk Factors for Skin Tumors, Melanoma Vary for Patients With Parkinson Disease
Investigators in Israel compared rates of risk factors for CMM, non?melanoma skin cancer (NMSC), and actinic keratosis (AK) among individuals with and without PD.